Form 4: Astria Therapeutics Director Sunil Agarwal Granted Stock Options

Director Sunil Agarwal of Astria Therapeutics, Inc. received stock options for 28,200 shares on April 8, 2024.

Summary

• On April 8, 2024, Sunil Agarwal, a director of Astria Therapeutics, Inc., was granted stock options to purchase 28,200 shares of the company's common stock.
• The exercise price of the options is $11.40 per share.
• The options vest in three equal annual installments, starting on the first anniversary of the grant date, contingent upon Agarwal's continued service as a director.
• The options expire on April 7, 2034.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting a standard compensation practice. It's neither particularly positive nor negative from an investment perspective.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards the company's success.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This is a standard practice for compensating board members in publicly traded companies, aligning their interests with shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotechnology industry to incentivize performance and align interests with shareholders.
• The vesting schedule of one-third annually over three years is a typical vesting arrangement.
• The size of the grant (28,200 shares) would need to be compared to grants at comparable companies to determine if it is above or below average.

Stakeholder Impact

• The stock option grant could have a minor dilutive effect on existing shareholders if the options are exercised.

Key Dates